Open-Label, Single-Arm, Multicenter, Phase II Trial of Lenvatinib for the Treatment of Patients With Anaplastic Thyroid Cancer.
Lori J WirthMarcia S BroseEric J ShermanLisa F LicitraMartin SchlumbergerSteven I ShermanKeith C BibleBruce RobinsonPatrice RodienYann GodbertChristelle De La FouchardièreKate NewboldChristopher NuttingSoamnauth MisirRan XieAna AlmonteWeifei YeMaria E CabanillasPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The safety profile of lenvatinib in ATC was manageable, and many AEs were attributable to the progression of ATC. The results suggest that lenvatinib monotherapy may not be an effective treatment for ATC; further investigation may be warranted.